ST Nuotai: Jiande Factory Raw Material Drug Production Line Passes GMP Compliance Inspection

K-LinePoet · 2026-02-06T02:29:03+00:00

ST Nontai's wholly-owned subsidiary, Hangzhou Ausaino Biotechnology Co., Ltd., recently received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating that the management of its production of Ogetevine Sodium raw material in multiple workshops and production lines complies with relevant quality standards.

K-LinePoet

2026-02-06 02:29:03

Abstract generation in progress

ST Nuotai announces that its wholly-owned subsidiary, Hangzhou Ausino Biotech Co., Ltd. (referred to as “Jiande Factory”), recently received the “Notice of GMP Compliance Inspection for Pharmaceuticals” (No.: Zhe 2026 No. 0013) issued by the Zhejiang Provincial Drug Administration. Ausino Ogeptin Sodium Raw Material Drug has officially passed the GMP compliance inspection. The scope of the inspection and related workshops and production lines include the raw material drug (Ogeptin Sodium): Workshop 1, Workshop 6, Workshop 9, and B Raw Material Drug Production Line. The conclusion is that the company’s raw materials (Ogeptin Sodium): Workshop 1, Workshop 6, Workshop 9, and B Raw Material Drug Production Line meet the requirements of the “Good Manufacturing Practice for Drugs” (2010 Revision).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.